Important Safety Information
| Prescribing Information

KYMBEE™ is the only deflazacort backed by Upsher-Smith’s comprehensive Promise of Support® Program to help children with Duchenne muscular dystrophy (DMD) get the treatment they need as easily, quickly, and reliably as possible.

Read the press release

KYMBEE (deflazacort) Tablets are a corticosteroid indicated for the treatment of DMD in patients 5 years of age and older.

Available strengths: 6 mg, 18 mg, 30 mg, and 36 mg tablets.

Selected Important Safety Information:
Who should not take KYMBEE Tablets? KYMBEE Tablets are contraindicated in patients with a hypersensitivity to deflazacort or any of the inactive ingredients.

We’re here to help you access deflazacort tablets for the child you love

For too long, access to deflazacort has been a worrisome challenge in caring for children with DMD.

With coverage navigation and access support for KYMBEE, the Upsher-Smith Promise of Support® Program strives to provide a clearer, more reliable path to deflazacort tablets therapy. We work together to help ensure access is more predictable for you and your child.

Manufactured by Upsher-Smith in Minnesota

As a trusted U.S.-based pharmaceutical company with over 100 years of experience, we deliver consistent supply and comprehensive support.

You can count on the Upsher-Smith Promise of Support® Program

Our Promise of Support® Program for KYMBEE powered by Orsini, reflects our deep commitment to delivering comprehensive support and resources, reducing barriers to access so you can focus on caring for the child you love.

Confidence through access and coverage navigation

  • $0 Copay* for eligible commercially insured patients
  • Prior authorization and appeal support to help accelerate access and reduce administrative burden
  • Pathways to access therapy, even when insurance challenges arise

Helping children start and stay on therapy

  • Quick Start medication supply enables patients to start therapy during the insurance approval process
  • Bridge medication supply provides access to medication while resolving coverage gaps or refill delays

Peace of mind for families

  • 24/7 access to a pharmacist for personalized help, education, and answers every step of the journey
  • Refill reminders available
  • Free home delivery of medication
  • Language translation available
  • Proactive weather monitoring to protect patients from gaps in therapy delivery

*Limitations apply.

Ask your doctor about

and the Promise of Support® Program powered by

If you or your doctor have questions about Kymbee, reach out to Upsher-Smith at 1-888-650-3789

IMPORTANT SAFETY INFORMATION FOR KYMBEE™ (deflazacort) Tablets
+

Who should not take KYMBEE?

Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE.

What is the most important information I should know about KYMBEE?

  • KYMBEE can cause changes in endocrine (hormone) function. Do not stop taking KYMBEE, or change the amount being taken, without first checking with a healthcare provider, as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency and steroid “withdrawal syndrome.” Acute adrenal insufficiency can occur if corticosteroids, including KYMBEE, are withdrawn abruptly, and can be life threatening. A steroid “withdrawal syndrome” may also occur following abrupt discontinuance of corticosteroids. For patients already taking corticosteroids during times of stress, the amount of KYMBEE prescribed may need to be increased.
  • There is an increased risk of infection when taking KYMBEE. Tell a healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Seek medical advice immediately if the patient develops fever or other signs of infection. Some infections can potentially be severe and life threatening. Patients should avoid exposure to chickenpox or measles and alert their healthcare provider immediately if they are exposed.
  • KYMBEE can cause an increase in blood pressure and water retention. If this occurs, dietary salt restriction and potassium therapy may be needed.
  • There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like KYMBEE.
  • KYMBEE can cause behavior and mood changes that can be severe. Seek medical attention if any behavioral or mood changes develop.
  • There is a risk of osteoporosis with prolonged use of KYMBEE, which can lead to fractures in the spine and in long bones.
  • KYMBEE may cause cataracts or glaucoma. A healthcare provider should monitor for these conditions if therapy is continued for more than 6 weeks.
  • Immunizations should be up-to-date according to immunization guidelines prior to starting therapy with KYMBEE. Live attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting KYMBEE. Live attenuated or live vaccines should not be used in patient staking KYMBEE.
  • KYMBEE can cause serious skin rashes. Seek medical attention at the first sign of a rash.
  • Rare instances of anaphylaxis, a severe allergic reaction, have occurred in patients receiving corticosteroid therapy, including KYMBEE.

Before taking KYMBEE, tell a healthcare provider about all medical conditions, including if the patient:

  • is pregnant or planning to become pregnant. KYMBEE can harm an unborn baby.
  • is breastfeeding or planning to breastfeed. KYMBEE may appear in breastmilk and could affect a nursing child.

Certain medications can cause an interaction with KYMBEE. Tell a healthcare provider about all the medicines you are taking, including over-the-counter medicines (such as insulin, aspirin, or other non-steroidal anti-inflammatory drugs), dietary supplements, and herbal products. Alternate treatment, dosage adjustment, and/or special test(s) may be needed during the treatment.

What are the side effects of KYMBEE?

The most common side effects include: facial puffiness or Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, frequent daytime urination, unwanted hair growth, abdominal obesity, and colds.These are not all of the possible side effects. Call a healthcare provider for medical advice about side effects.

This safety information is not comprehensive.

Please see the full Prescribing Information for more information on KYMBEE. You can also visit www.upsher-smith.com or call 1-888-650-3789.

You are encouraged to report suspected adverse reactions to the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088.

What is KYMBEE?

KYMBEE (deflazacort) Tablets are a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.